The polymorphisms can predict the adverse effects of chemotherapy in patients with colorectal cancer
| Project/Area Number |
19591545
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Yamaguchi University |
|---|
Principal Investigator |
HAZAMA Shoichi Yamaguchi University, 大学院・医学系研究科, 准教授 (50253159)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OKAYAMA Naoko 山口大学, 医学部附属病院, 副臨床・衛生検査技師長 (40420541)
SAKAMOTO Kazuhiko 山口大学, 医学部附属病院, 助教 (50420526)
|
|---|
| Project Period (FY) |
2007 – 2008
|
| Project Status |
Completed (Fiscal Year 2008)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2008: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2007: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | 大腸癌 / 化学療法 / 遺伝子多型 / 毒性 / UGT1Ai / イリノテカン / UGT1A1 / *28 / *6 / ^*28 / ^*6 |
|---|
| Research Abstract |
イリノテカンを含む大腸癌化学療法の第I相試験を行い、イリノテカンの推奨投与量をUGT1A1^*28遺伝子型別に決定した。推奨投与量に基づき、第II相試験を行った。その結果、^*28の有無に関わらず、約30%の強い毒性を認めた。ここで毒性の出た患者と毒性の出なかった患者の遺伝子多型を、さらに詳細に検討した結果、UGT1A1^*6, UGT1A7^*3,UGT1A9^*22の遺伝子型が毒性発現に関わっていることが判明した。これらの遺伝子多型を組み合わせて毒性を予測する判別式を作成、またこれら多くの遺伝子多型を判別するチップを開発し、現在両者ともに特許申請中である。
|
Report
(3 results)
Research Products
(15 results)
-
-
-
-
-
-
-
[Journal Article] UGT1As polymorphisms predict toxicity in colorectal cancer patients treated with different recommended doses of irinotecan oriented by UGT1A1*28 polymorphism based on previous phase I study2007
Author(s)
S. Hazama, H. Kondo, S. Yoshida, R. Shimizu, H. Ozasa, T. Yamamoto, A. Araki, S. Yoshino, N. Okayama, Y. Hinoda, M. Oka
-
Journal Title
Journal of Clinical Oncology 25
Pages: 14511-14511
Related Report
Peer Reviewed
-
-
-
[Presentation] UGT1A1 *6 is a predictive marker of severe neutropenia for metastatic CRC patients received FOLFIRI in JAPAN2008
Author(s)
S. Hazama, Y. Okuyama, T. Kato, K. Takahashi, H. Nozawa, N. Okayama, Y. Hinoda, M. Oka, J. Sakamoto, H. Mishima
Organizer
The 33rd ESMO (European society of medical oncology) Congress
Place of Presentation
Stockholm, Sweden
Related Report
-
-
[Presentation] UGT1As polymorphisms predict toxicity in colorectal cancer patients treated with different recommended doses of irinotecan oriented by UGT1A1*28 polymorphism based on previous phase I study2007
Author(s)
S. Hazama, H. Kondo, S. Yoshida, R. Shimizu, H. Ozasa, T. Yamamoto, A. Araki, S. Yoshino, N. Okayama, Y. Hinoda, M. Oka
Organizer
2007 ASCO Annual Meeting
Place of Presentation
Chicago/IL/USA
Related Report
-
-
-
